At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 111 enrolled
Drug / intervention
Sitravatinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib as Monotherapy and in Combination With Tislelizumab in Patients With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
In Brief
A Phase 2 clinical trial evaluating Sitravatinib and Tislelizumab for Carcinoma, Hepatocellular and Gastric/Gastroesophageal Junction Cancer. Completed, enrolled 111 participants across 18 sites.
Detailed Summary
The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of sitravatinib as monotherapy and in combination with tislelizumab in participants with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC) or gastric/gastroesophageal junction (G/GEJ) cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartFeb 2019
First PostedMay 2019
Primary CompletionMar 2023
TodayJul 2026
First PostedMay 8, 2019
Enrollment StartFeb 28, 2019
Primary CompletionMar 31, 2023
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 7.1 years ago
Interventions
Sitravatinibdrug
Administered orally as a capsule
Tislelizumabdrug
Administered intravenously